Clinical Trials Browser

NIH × Bevacizumab × Breast × Clear all

NCT00433511 2026-03-03

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

Phase 3 Active not recruiting

4,994 enrolled 11 charts

Breast Adenocarcinoma

NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Phase 2 Completed

454 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00601900 2025-05-23

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Phase 3 Completed

394 enrolled 11 charts

Breast Neoplasms

NCT00520975 2025-03-28

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase 3 Terminated

96 enrolled 16 charts

Breast Neoplasms

NCT00785291 2022-10-10

Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

Phase 3 Completed

799 enrolled 18 charts

Breast Neoplasms

NCT00054132 2017-07-24

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

Phase 2 Completed

38 enrolled 10 charts

Breast Neoplasms

NCT00016549 2017-07-02

Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer

Phase 2 Completed

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00368875 2015-11-05

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

Phase 1/2 Completed

54 enrolled 9 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00119262 2014-05-15

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Phase 2 Completed

226 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00436709 2014-01-06

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

Phase NA Unknown

Breast Neoplasms, Breast Neoplasms, Male

NCT00404404 2013-12-18

ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT00055861 2013-06-04

Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00017394 2013-01-17

Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male